Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) based upon long-term data evaluating the safety and efficacy of ...

According to the U.S. Centers for Disease Control and Prevention (CDC), in 2022, the majority of the 28.8 million U.S. adults ...

Abu Dhabi: Behind every recovery from addiction lies a story of resilience, hope and transformation. At the National ...

"Relapse prevention is a critical goal for the long-term care and management of this debilitating disorder," said Bill Martin, Global Therapeutic Area Head of Neuroscience at Johnson & Johnson ...

Long-Term Data Reinforce Caplyta’s Role in Neuropsychiatric Care “Relapse prevention is a critical goal for the long-term care and management of this debilitating disorder,” said Bill Martin, PhD, ...

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo ...

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite ...

The plan is broken down into five priorities: Social determinant of health, prevention, harm reduction, treatment and recovery.

Hamilton County's new risk-based supervision model aims to reduce recidivism by tailoring supervision to an offender's risk ...